Unlock instant, AI-driven research and patent intelligence for your innovation.

Method and composition for the treatment of cancer

a cancer and composition technology, applied in the field of cancer composition and treatment methods, can solve the problem of tumors not growing back

Inactive Publication Date: 2005-08-04
DANA FARBER CANCER INST INC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method of treating tumors in mammals by combining two types of drugs, one that targets cells in the G1 and / or S phase (β-lapachone or its derivatives) and another that targets cells in the G2 / M phase (paclitaxel or its derivatives). This combination results in a stronger reduction in tumor size and volume compared to either drug alone, and no signs of toxicity or weight loss were observed in the mammals treated. The method is particularly useful for treating metastatic cancer that is resistant to other chemotherapy drugs. The combination of β-lapachone and paclitaxel is a preferred treatment.

Problems solved by technology

Furthermore, the tumors did not grow back in several months of observation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and composition for the treatment of cancer
  • Method and composition for the treatment of cancer
  • Method and composition for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

examples

[0074] In Vivo Testing

[0075] Experiment 1

[0076] Brief description of the tumor model (Cannistra model Cannistra, et al., Cancer Res., 57:1228-1232 (1997)—Ovary cancer is a highly lethal disease. Metastases occurs predominantly by widespread implantation throughout the abdominal cavity. To test the efficacy of β-lapachone alone and in combination with TAXOL®, we used human ovary cancer cells (36M2) that were originally derived from a patient with malignant ascites. Inoculation of these cells into female nude mice recapitulates the metastatic process as observed in patients.

[0077] This is a highly metastatic and malignant cancer cell model. In general, tumor nodules on peritoneum and malignant ascites develop 4 to 5 weeks after an inoculation of 10×106 cells. Metastatic foci can be seen from one week after inoculation.

Animals

[0078] Athymic female nude (nu / nu) were used throughout the experiments.

Drugs

[0079]β-Lapachone was formulated into solution by using lipidol, a medium ag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
time periodaaaaaaaaaa
time periodaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

We have discovered that the administration of a G1 and / or S phase drug such as β-lapachone in combination with a G2 / M drug such as a taxane derivative such as paclitaxel resulted in a unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a β-lapachone, or a derivative or analog thereof.

Description

RELATED APPLICATIONS [0001] This patent application is a continuation of U.S. patent application Ser. No. 10 / 683,199, filed Oct. 9, 2003 which is a continuation of U.S. patent application Ser. No. 09 / 958,479, filed Feb. 7, 2002, now U.S. Pat. No. 6,664,288, which is a 371 of PCT / US00 / 10169, filed Apr. 14, 2000, which claims the benefit of U.S. Provisional Application No. 60 / 129,261, filed Apr. 14, 1999. The contents of these applications are incorporated herein by reference in their entireties.BACKGROUND OF THE INVENTION [0002] The treatment of cancer has thus far proved problematic. While “cancers” share many characteristics in common, each particular cancer has its own specific characteristics. Genetics and environmental factors have a complex interplay in severity and prognosis of treatment. Thus, treatment must be carefully tailored. [0003] Certain pharmaceutical treatments have proved useful for one form of cancer, but not others (Hollad and Frei, et al, Cancer Medicine, 4th ed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/122A61K31/337A61K31/35A61K31/352A61K31/4184A61K31/427C07D311/92A61K31/437A61K31/704A61K31/7042A61K38/00A61K45/00A61K45/06A61P35/00
CPCA61K31/122A61K31/337A61K31/35A61K45/06Y10S514/922A61K31/335A61K2300/00A61P35/00A61P35/04A61P43/00
Inventor PARDEE, ARTHUR B.LI, CHIANG J.LI, YOUZHI
Owner DANA FARBER CANCER INST INC